Allarity Therapeutics, Inc. (ALLR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 28, 2023, by Allarity Therapeutics, Inc., a Delaware corporation. The report details a corporate action approved by stockholders at a special meeting on June 23, 2023, and executed on June 28, 2023.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure adjustment.
Material Changes
- Reverse Stock Split: The Company effected a 1-for-40 reverse stock split of its common stock, effective 4:05 p.m. (New York time) on June 28, 2023.
- Share Count Reduction: The number of outstanding shares was reduced from 20,142,633 to approximately 503,566 shares.
- Fractional Shares: No fractional shares were issued; any fractional entitlements were rounded up to the next whole number.
- Authorized Shares: The total number of authorized shares remains unchanged at 750,000,000.
- Trading Details: Common stock began trading on a split-adjusted basis on the Nasdaq Capital Market on June 29, 2023, under the symbol "ALLR" with a new CUSIP number (016744302).
- Equity Adjustments: Proportionate adjustments were made to the exercise prices and share counts for outstanding stock options and shares reserved under the 2021 Equity Incentive Plan.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure regarding the reverse stock split. The Company noted that the Board was granted discretion to set a split ratio between 1-for-15 and 1-for-50, ultimately selecting 1-for-40.
Investor Verification Checklist
- Verify the new CUSIP number (016744302) for trading and settlement purposes.
- Confirm the adjusted number of shares held in brokerage accounts following the 1-for-40 consolidation.
- Review the adjusted exercise prices and share quantities for any outstanding stock options or warrants.
- Check the Company's subsequent filings for updated financial statements reflecting the new share count.